Novo Nordisk A/S (NVO) Operating Margin: 45.21%
Is Novo Nordisk A/S’s operating margin high or low?
Novo Nordisk A/S's operating margin of 45.21% is in line with its 5-year average of 42.70%, near the high end of its 5-year range (41.30%–45.21%).
As of Wednesday, June 17, 2026. 5.77% above its 12-month average of 42.74%.
NVO Operating Margin Chart
NVO Average Operating Margin Chart
NVO Current vs Average Operating Margin Chart
NVO Operating Margin Metrics
OPERATING MARGIN
45.21%
OPERATING MARGIN AVG TTM
42.74%
OPERATING MARGIN AVG 3Y
42.98%
OPERATING MARGIN AVG 5Y
42.70%
OPERATING MARGIN AVG 10Y
43.13%
OPERATING MARGIN AVG 15Y
41.50%
OPERATING MARGIN AVG 20Y
37.09%
CURRENT VS TTM AVG
+5.77%
CURRENT VS 3Y AVG
+5.18%
CURRENT VS 5Y AVG
+5.87%
CURRENT VS 10Y AVG
+4.82%
CURRENT VS 15Y AVG
+8.95%
CURRENT VS 20Y AVG
+21.91%
NVO Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.53B | 45.21% | 42.74% | 42.98% | 42.70% |
| Amgen Inc. (AMGN)vs › | $187.59B | 31.63% | 25.38% | 28.78% | 30.08% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 17.76% | 18.04% | 18.11% | 20.54% |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 38.26% | 22.76% | 25.11% | 25.54% |
| Abbott Laboratories (ABT)vs › | $157.84B | 18.17% | 17.21% | 17.41% | 17.71% |
| Pfizer Inc. (PFE)vs › | $148.41B | 23.45% | 25.29% | 24.23% | 24.05% |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 30.45% | 28.70% | 26.89% | 27.25% |
| Danaher Corporation (DHR)vs › | $128.06B | 20.95% | 21.31% | 23.25% | 23.28% |
| CVS Health Corporation (CVS)vs › | $127.73B | 1.46% | 2.43% | 2.79% | 3.48% |
| Stryker Corporation (SYK)vs › | $119.06B | 21.34% | 20.93% | 20.75% | 21.02% |
Operating Efficiency
Gross Margin
81.8%
Operating Margin
45.2%
Novo Nordisk A/S Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Operating Margin FAQ
- What is the operating margin for Novo Nordisk A/S (NVO)?
- The operating margin for NVO stock is 45.21%.
- Is Novo Nordisk A/S's operating margin high or low?
- Novo Nordisk A/S's operating margin of 45.21% is in line with its 5-year average of 42.70%, near the high end of its 5-year range (41.30%–45.21%).
- What is the TTM average operating margin for Novo Nordisk A/S (NVO)?
- The TTM average operating margin for NVO stock is 42.74%.
- What is the 3Y average operating margin for Novo Nordisk A/S (NVO)?
- The 3Y average operating margin for NVO stock is 42.98%.
- What is the 5Y average operating margin for Novo Nordisk A/S (NVO)?
- The 5Y average operating margin for NVO stock is 42.70%.
- What is the 10Y average operating margin for Novo Nordisk A/S (NVO)?
- The 10Y average operating margin for NVO stock is 43.13%.
- What is the 15Y average operating margin for Novo Nordisk A/S (NVO)?
- The 15Y average operating margin for NVO stock is 41.50%.
- What is the 20Y average operating margin for Novo Nordisk A/S (NVO)?
- The 20Y average operating margin for NVO stock is 37.09%.
Novo Nordisk A/S Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-12-31 | 41.30% |
| 2024-12-31 | 44.19% |
| 2023-12-31 | 44.16% |
| 2022-12-31 | 42.28% |
| 2021-12-31 | 41.65% |
| 2020-12-31 | 42.64% |
| 2019-12-31 | 43.01% |
| 2018-12-31 | 42.25% |
| 2017-12-31 | 43.84% |
| 2016-12-31 | 43.33% |
| 2015-12-31 | 45.81% |
| 2014-12-31 | 38.84% |
| 2013-12-31 | 37.68% |
| 2012-12-31 | 37.77% |
| 2011-12-31 | 33.72% |
| 2010-12-31 | 31.08% |
| 2009-12-31 | 29.24% |
| 2008-12-31 | 27.16% |
| 2007-12-31 | 21.38% |
| 2006-12-31 | 23.53% |
| 2005-12-31 | 23.95% |
| 2004-12-31 | 24.05% |
| 2003-12-31 | 24.06% |
| 2002-12-31 | 23.75% |
| 2001-12-31 | 23.60% |
| 2000-12-31 | 20.39% |
| 1999-12-31 | 17.76% |
| 1998-12-31 | 10.50% |
| 1997-12-31 | 13.74% |
| 1996-12-31 | 13.29% |
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar